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Chemoradiotherapy (CRT) for esophageal cancer is disadvantageous because of a high 
locoregional failure rate. Detecting early small recurrent cancers at the primary site is 
necessary for potential salvage treatment. However, most endoscopists are inexperienced and 
therefore a role for surveillance endoscopy after complete remission (CR) has not been 
established. We retrospectively evaluated serial surveillance endoscopic images from 
patients eventually proved to have primary-site recurrence in order to identify useful 
endoscopic features for early diagnosis. 
Methods: 
From January 2000 to December 2004, 303 patients with esophageal squamous cell 
carcinoma underwent definitive CRT and 133 of them achieved CR. The surveillance 
endoscopic images stored at intervals of 1–3 months for the 16 patients with recurrence only 
at the primary tumor site and the 61 patients with no recurrence were collected for 
reexamination. 
Results: 
Among 133 patients who achieved CR, 16 (12%) developed only local recurrence at the 
primary site. Thirteen of the 16 primary-site recurrent tumors (81%) appeared as submucosal 
tumors (SMT), with the remaining appearing as erosions or mild strictures. Eighty-one 
percent of biopsy-proved recurrences were preceded by newly developed lesions such as 
SMT, erosions, or mild strictures detected by earlier surveillance endoscopies. For all 77 
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patients achieving CR with no metastasis, 86% of the evolving SMT with negative biopsies 
were eventually confirmed as cancer at later endoscopies. Thirteen of the 21 evolving lesions 
were subsequently confirmed as recurrent cancer. 
Conclusions: 
Early primary-site recurrence of esophageal cancer after a complete response to CRT is 
detectable with frequent endoscopic surveillance. SMT appearance is a useful endoscopic 
sign of early recurrence, as well as a predictor of subsequent diagnosis of recurrence. 
 




Definitive chemoradiotherapy (CRT) is widely accepted as a standard treatment option 
in the management of locally advanced esophageal cancer because of its high response rate 
and significant survival benefit.1,2 A major drawback to this nonsurgical approach is 
locoregional treatment failure. At least 40% of patients undergoing CRT experienced local 
failure, some of whom did not develop distant metastases.1,3–5 
These primary-site recurrence patients are traditionally managed with salvage 
esophagectomy for a chance of long-term survival, particularly in those with an earlier 
pathological stage (T1N0 and T2N0).6,7 However, high perisurgical mortality and morbidity 
rates are major concerns.7,8 Recently developed nonsurgical techniques, such as salvage 
endoscopic mucosal resection and photodynamic therapy, have the advantages of greater 
safety and fewer treatment-related sequelae, while conferring promising survival benefits for 
local failures after definitive CRT.9,10 Technically, endoscopic mucosal resection and 
photodynamic therapy are feasible only when the volume of the locally recurrent tumor is 
small enough to be amenable to these endoscopy-based procedures. Therefore, the 
application of these newer treatments depends crucially on the ability to identify early 
recurrent tumors by endoscopy. 
A strategy of frequent surveillance endoscopy initiated early after remission of the 
cancer should theoretically improve the chances of detecting primary-site recurrent tumors in 
their early stages. This requires the prompt recognition of minute tumors arising from the 
former neoplastic bed, instead of from the uninvolved normal esophageal mucosa. However, 
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the complete regression of cancer cells results in residual fibrosis, radiation-induced tissue 
injury, and the distortion of normal microstructures,11,12 which may render relapsing 
neoplastic growth morphologically different from typical primary tumors. Apparently, most 
endoscopists are inexperienced in hunting for these difficult lesions. To our knowledge, no 
study of the skills in endoscopic detection of such lesions has been published. Not 
surprisingly, a follow-up endoscopy after the completion of CRT is considered “optional” in 
the National Comprehensive Cancer Network clinical practice guidelines for esophageal 
cancer.13 We believe that a reliable endoscopic diagnostic technique is necessary to support a 
strategy of intense endoscopic follow-ups. 
As a cancer referral and research hospital, our institute is unique in its implementation 
of a vigorous endoscopic follow-up program after primary treatment for all patients with 
esophageal cancer. Therefore, it is possible to analyze the filed imaging data of endoscopic 
monitoring on the post-CRT mucosa. In the present study, we aimed to identify useful 
endoscopic findings through reviewing the image data pool to predict recurrent esophageal 
cancers limited to the primary site after complete remission (CR) is achieved by CRT. 
MATERIALS AND METHODS 
Patient population 
Between January 2000 and December 2004, 303 patients with esophageal squamous 
cell carcinoma underwent definitive CRT at the National Cancer Center Hospital East, 
Kashiwa, Japan. The CRT consisted of 50.4–60 Gy irradiation, together with two cycles of 
continuous infusion with 5-fluorouracil (5FU) and cisplatin. Up to four courses of CRT were 
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added for those patients who showed a good initial response to treatment.9 
Response to treatment was assessed at the completion of CRT. CR was defined when 
all the following criteria were met: (1) the disappearance of the tumor lesion or ulcer at the 
primary site, with negative biopsies; (2) no esophageal stricture or any condition that 
prevented a thorough endoscopic examination of the whole esophagus; (3) no remaining 
measurable disease or distant metastasis on computer tomography and chest 
roentgenography; and (4) these criteria were met for at least four weeks. 
Of the 303 patients, 133 (43.9%) were defined as being in CR at the completion of CRT. 
Of these 133 patients, 110 were men, with a median age of 62 years. Pretreatment staging of 
their esophageal cancers was determined with the tumor-node-metastasis classification of the 
International Union Against Cancer.14 Seventy (52.6%) patients had T3 tumors; most 
patients had N1 (65.4%) or M0 (92.5%) disease. Forty-five (33.8%) and 62 (46.6%) patients 
were classified as clinical stages II and III, respectively (Table 1). 
Study design 
After achieving CR, initial follow-up endoscopy to confirm CR was scheduled within 
at most 1–2 months for each patient, accompanied with other necessary studies for the 
assessment of metastases. After the confirmation of CR, follow-up endoscopy was scheduled 
every 2–3 months for the first year and every 4–6 months for two years thereafter. Lugol 
staining and multiple biopsies at the primary site were routinely required.15 The diagnosis of 
local recurrence was determined by a positive biopsy. 
Of the 133 CR patients, 61 had no recurrence, 56 developed lymph node or distant 
8 
 
metastases, and the remaining 16 developed local recurrence at the primary tumor site with 
no evidence of metastasis. We excluded the 56 patients with lymph node or distant 
metastases from this study because for them, evaluation of the primary site was not important 
and only those patients eligible for salvage treatment on local tumors were of interest. 
Therefore, the endoscopic images of the remaining 77 patients were retrospectively enrolled. 
This population comprised patients with esophageal squamous cell carcinoma who achieved 
CR after the initial CRT and developed no metastasis during follow-up, regardless of local 
recurrence. All of the filed endoscopic images stored after achieving CR, both conventional 
endoscopy and Lugol-stained chromoendoscopy, were retrospectively collected for 
reexamination. The stored endoscopic images were evaluated by consensus among three 
endoscopists experienced in upper gastrointestinal cancer diagnosis (K. T., M. M., K. M.). 
RESULTS 
Upon the diagnosis of primary-site recurrence for the 16 patients, 13 (81%) had 
endoscopic findings resembling SMT, typically a focal bulge mostly covered by 
normal-appearing mucosa (Fig. 1A).16 Eleven of the 13 tumors contained central eroded 
areas recognized as ulcers or erosions (Fig. 1B, 1C). The remaining three tumors were 
detected as flat erosions without features of SMT (Table 2). 
Images of surveillance endoscopies performed at intervals between CR and the 
diagnosis of recurrence in the 16 patients were sequentially examined. Newly developed 
gross lesions at the primary site with negative biopsies were interpreted as recurrent lesions. 
Evolving lesions were discovered in 13 (81%) patients, including six (38% of the 16 patients) 
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SMT, five (31%) erosions, and two (12%) mild luminal strictures (Table 3). 
For all 77 patients achieving CR and free of metastasis, lesions newly developed 
between CR and the most recent endoscopic surveillance were considered evolving lesions. 
Therefore, an evolving lesion may be eventually proven to be a recurrence or remain 
biopsy-negative at the most recent endoscopy. Six of the seven (86%) evolving SMT were 
subsequently confirmed as recurrent cancer by follow-up endoscopic biopsies. Similarly, five 
of eight (63%) evolving erosions and two of six (33%) evolving mild strictures were finally 
confirmed as recurrence. Fifty-six patients were never found to have evolving lesions 
throughout the follow-up, including three (5%) who were confirmed as recurrence upon the 
first appearance of an endoscopic lesion. In total, eight of the 21 (38%) patients who 
developed evolving lesions remained biopsy-negative at their most recent endoscopic 
follow-up (Table 4). 
DISCUSSION 
We discovered that the most frequent (81%) endoscopic indicator of primary-site 
recurrence at its earliest possible stage for a histological diagnosis is SMT. Eighty-one 
percent of biopsy-proved recurrences were preceded by newly developed lesions such as 
SMT, erosions, or mild strictures detectable with surveillance endoscopies. Most (86%) 
evolving SMT with negative biopsies were eventually confirmed as cancer at later 
endoscopies, but the proportions were lower for other evolving lesions such as erosions (63%) 
and strictures (33%). This is the first study to describe the morphological changes of early 
recurring tumors by serial endoscopic observations at short intervals. Our findings will be 
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helpful for improving the skills to detect potentially treatable primary-site recurrence after 
definitive CRT for esophageal squamous cell carcinoma. 
For the endoscopic diagnosis of primary esophageal cancer, several features have been 
previously described to detect early stage squamous cell carcinoma: localized mucosal 
erosions in contrast to normal surrounding mucosa; circumscribed mucosal protuberances 
with irregular configurations; focal areas of mucosal coarsening and congestion; and, rarely, 
white mucosal plaques.16 However, these features are not reliable when applied to early 
recurrent tumors arising from the mucosal bed of a former primary cancer that regressed after 
CRT. The original esophageal layering and vascular structures have been disrupted by the 
primary tumor. Furthermore, the expansion and arrangement of recurring neoplastic cells are 
disrupted by tissue reactions to previous chemotherapy and radiotherapy, as well as by 
subsequent repair processes. Tumor necrosis, foam cell formation, vascular granulation, 
inflammatory exudation and fibrosis are frequent histological sequelae of CRT.17,18 The 
minute foci of the initial neoplastic growth may arise from scattered residual cancer cells in 
deeper tissues, rather than from the superficial mucosal layer, as does the primary cancer.11 
These factors have largely precluded endoscopic ultrasound as a feasible tool in the 
assessment of residual or recurrent esophageal cancers.19,20 For the same reason, the 
endoscopic diagnostic features for recurrent tumors are likely to be different from those for 
primary tumors. 
We speculate that most of the SMT lesions discovered in our study were formed by 
expanding tumor cells in the submucosal layers, but barely reached the luminal surface 
because of their depth and constraining fibrosis. Although the overlying mucosa appeared 
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normal, they manifest their first sign by bulging outward. Malignant cells can be captured by 
biopsy forceps only when they reach the surface in sufficient numbers, or more efficiently, 
destroy the surface to make an erosion. This might explain why all of the six newly 
developed SMT yielded negative results at their first biopsies but eventually proved to be 
recurrences (Table 3). 
Several previous studies have aimed to improve the detection of local recurrence by 
measures other than endoscopy. In addition to pretreatment staging, 
F-18-fluorodeoxyglucose–positron emission tomography (FDG–PET) is highly sensitive (up 
to 96%) in detecting recurrent esophageal cancer, but with somewhat lower specificity 
(68%–82%).21–23 However, its utility in detecting locoregional recurrence is limited by its 
low specificity (57%–75%) for postesophagectomy patients. Postsurgical inflammation and 
anatomical changes are largely responsible for the false positivity. Detecting small residual 
or early recurrent cancers is even more challenging because low tumor volume could greatly 
reduce the sensitivity of FDG–PET. Moreover, such lesions are not distinguishable from 
post-CRT inflammation or regional lymph-node metastasis.24,25 
The results of our study disagree with the conventional belief that endoscopy is of 
limited utility in the management of esophageal cancer after CRT.13,26 We believe that routine 
endoscopy, particularly focused on the primary tumor site, is advisable for all patients with 
esophageal squamous cell carcinoma after the completion of CRT. We also suggest regular 
endoscopic surveillance at least every three months for those who have achieved CR. The 
occurrence of SMT-like lesions after CR is an alarming sign that deserves intensive 
investigation and follow-up if a modality of salvage treatment is available. Any evolving 
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lesion at the primary site with negative biopsy should be followed closely. 
Our retrospective study design has introduced a knowledge bias because the evaluating 
endoscopists were not totally blinded to the outcomes. Therefore, a randomized controlled 
trial comparing the clinical outcomes is necessary to establish the role of surveillance 
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Table 1 Clinical data of 133 patients achieving CR with definitive CRT 
Characteristic  No. patients % 
Sex    
  Male  110 82.7 
  Female  23 17.3 
Age (years)    
  Mean 62   
  Range 39–76   
T stage    
  T1  30 22.6 
  T2  21 15.8 
  T3  70 52.6 
  T4  12   9.0 
N stage    
  N0  46  34.6 
  N1  87  65.4 
M stage    
  M0  123  92.5 
  M1  10   7.5 
Clinical stage    
  I  16 12.0 
  II  45 33.8 
  III  62 46.6 
  IV  10   7.5 
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Macroscopic classification    
  Type 0  30  22.6 
  Type 1  19  14.3 
  Type 2  60  45.1 





Table 2 Endoscopic findings at primary-site with biopsy-proven recurrence 
Endoscopic finding No. patients % 
SMT 13 81 
SMT with erosion or ulceration 




Erosion 3 19 
Total 16 100 





Table 3 Endoscopic findings of newly developed lesion for primary-site recurrent 
tumors 
Preceding newly developed 
lesions with negative biopsies 
Findings at diagnosis of 
recurrence 
No. patients 
SMT SMT 6 
Erosion SMT 4 
Erosion Erosion 1 
Mild stricture SMT 2 
No newly developed lesion SMT 1 
No newly developed lesion Erosion 2 
Total  16 





Table 4 Primary-site biopsy result of the latest surveillance endoscopy for patients 
who achieved CR and remained free of metastasis 
Evolving lesion 
found at preceding 
endoscopies 
No. patients Biopsy result of the 
latest endoscopy 
No. patients 
SMT 7 (9%) Recurrence 6 (86%) 
  Negative 1 (14%) 
Erosion 8 (10%) Recurrence 5 (63%) 
  Negative 3 (37%) 
Mild stricture 6 (8%) Recurrence 2 (33%) 
  Negative 4 (67%) 
No evolving lesion 56 (73%) Recurrence 3 (5%) 
  Negative 53 (95%) 
Total 77 (100%)   





Fig. 1 Initially growing recurrent esophageal cancer at the primary tumor site after 
complete remission was achieved with chemoradiotherapy may be detected by endoscopy, 
with features of a submucosal tumor (A), a submucosal tumor with superficial ulcer (B), or a 
flat erosion (C). 
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